Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal CancerBusiness Wire • 03/18/24
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of DiseaseBusiness Wire • 03/14/24
Natera to Present New Data at the 2024 SGO Annual Meeting on Women's Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast CancersBusiness Wire • 03/12/24
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS PlanBusiness Wire • 03/07/24
Compared to Estimates, Natera (NTRA) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/29/24
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure TestsBusiness Wire • 02/27/24
Medicare Extends Coverage of Natera's Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast CancerBusiness Wire • 02/26/24
New Publication Demonstrates Signatera's Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung CancerBusiness Wire • 01/30/24
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past RoyaltiesBusiness Wire • 01/29/24
Nature Medicine Publishes Two Studies Highlighting Signatera's Clinical Utility in Patients with Gastrointestinal MalignanciesBusiness Wire • 01/25/24
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera's Clinical Utility in CRCBusiness Wire • 01/18/24
Natera Hits A Nearly Two-Year High After Notching A Win In A Patent BattleInvestors Business Daily • 01/17/24